C2C

 

Title: C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance

Status: Ongoing, closed to recruitment

 

Sites :
Territories: UK, Belgium, France, Germany, Italy, Netherlands, Spain, Switzerland & Sweden
Status: Ongoing, closed to recruitment

​

Abstract presented as poster at EACS 2023 -

Title : Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe:  Data from COMBINE-2 Study

Authors : ​Anton Pozniak,1 Gayathri Sridhar,2 Lambert Assoumou,1 Lionel Piroth,3 Dominique Braun,4 Carl Fletcher,5 Leigh Ragone,2 Ajay Shah,6 Jean van Wyk,7 Vani Vannappagari2, on behalf of the C2C study group 1The European treatment network for HIV, hepatitis and global infectious diseases (NEAT ID), London, UK; 2ViiV Healthcare, Durham, NC, USA; 3CHU Dijon-Bourgogne, Dijon Cedex, France; 4Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 5 Research Organization (KC) Ltd., London, UK; 6GlaxoSmithKline, Brentford, Middlesex, UK; 7ViiV Healthcare, London, England, UK

​

IAS 2024 - Poster Presentation

Title : Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Cohort Study

Author : Anton Pozniak1, Gayathri Sridhar2, Lambert Assoumou1,3, Lionel Piroth4, Dominique Braun5, Carl Fletcher6, Leigh Ragone2, Ajay Shah7, Jean van Wyk8, Vani Vannappagari2

​